ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakanishi, R.
Right arrow Articles by Yasumoto, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakanishi, R.
Right arrow Articles by Yasumoto, K.

Ann Thorac Surg 1997;64:342-348
© 1997 The Society of Thoracic Surgeons

Original Articles: General Thoracic

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non–Small Cell Lung Cancer

Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu, MD, Hideyuki Watanabe, MD, Hajime Nakata, MD, Kosei Yasumoto, MD

Second Department of Surgery, and Department of Radiology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

Accepted for publication February 6, 1997.

Background. The treatment strategy for patients with non–small cell lung cancer and clinically negative, but surgically detected mediastinal lymph node metastasis (surgically discovered N2 disease) is controversial.

Methods. From August 1979 through December 1994, 53 patients with non–small cell lung cancer were found to have surgically discovered N2 disease. We retrospectively studied the clinical characteristics and the factors that influenced the prognosis in these patients.

Results. The 3-year and 5-year survival rates and the median survival for the 53 patients with surgically discovered N2 disease were 44%, 21%, and 26 months. Two thirds of the patients had adenocarcinoma. Only complete resection affected long-term survival; adjuvant therapy had no effect on survival. In regard to lymph node status, a single metastatic focus in the aortic area was associated with long-term survival.

Conclusions. Patients with adenocarcinoma may require histologic determination of N2 disease. Complete resection, including extensive and complete mediastinal lymph node dissection, is warranted in patients with surgically discovered N2 disease. In particular, when the aortic lymph node (including stations 5 and 6) alone is involved, the patients should undergo as complete a resection as possible.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
Z. Mansour, E. A. Kochetkova, N. Santelmo, X. Ducrocq, E. Quoix, J.-M. Wihlm, and G. Massard
Persistent n2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy.
Ann. Thorac. Surg., July 1, 2008; 86(1): 228 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. Riquet, P. Bagan, F. Le Pimpec Barthes, E. Banu, F. Scotte, C. Foucault, A. Dujon, and C. Danel
Completely Resected Non-Small Cell Lung Cancer: Reconsidering Prognostic Value and Significance of N2 Metastases
Ann. Thorac. Surg., December 1, 2007; 84(6): 1818 - 1824.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. J. Cerfolio, A. S. Bryant, and M. A. Eloubeidi
Accessing the Aortopulmonary Window (#5) and the Paraaortic (#6) Lymph Nodes in Patients With Non-Small Cell Lung Cancer
Ann. Thorac. Surg., September 1, 2007; 84(3): 940 - 945.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
J. Kuzdzal, M. Zielinski, B. Papla, A. Urbanik, W. Wojciechowski, M. Narski, A. Szlubowski, and L. Hauer
The transcervical extended mediastinal lymphadenectomy versus cervical mediastinoscopy in non-small cell lung cancer staging
Eur. J. Cardiothorac. Surg., January 1, 2007; 31(1): 88 - 94.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
P. Misthos, E. Sepsas, K. Athanassiadi, S. Kakaris, and I. Skottis
Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer
Eur. J. Cardiothorac. Surg., April 1, 2004; 25(4): 502 - 508.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. Inoue, N. Sawabata, S.-i. Takeda, M. Ohta, Y. Ohno, and H. Maeda
Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe
J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1100 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. K. Ferguson
Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis
J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1935 - 1942.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
K. Suzuki, K. Nagai, J. Yoshida, M. Nishimura, K. Takahashi, and Y. Nishiwaki
THE PROGNOSIS OF SURGICALLY RESECTED N2 NON-SMALL CELL LUNGCANCER: THE IMPORTANCE OF CLINICAL N STATUS
J. Thorac. Cardiovasc. Surg., July 1, 1999; 118(1): 145 - 153.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
I. Yoshino, R. Nakanishi, T. Osaki, M. Takenoyama, S. Taga, T. Hanagiri, and K. Yasumoto
Unfavorable Prognosis of Patients With Stage II Non-small Cell Lung Cancer Associated With Macroscopic Nodal Metastases
Chest, July 1, 1999; 116(1): 144 - 149.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1997 by The Society of Thoracic Surgeons.